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Abstract: Mucus provides protective functions in the gastrointestinal tract and plays an 
important role in the adhesion of microorganisms to host surfaces. Mucin glycoproteins 
polymerize,  forming  a  framework  to  which  certain  microbial  populations  can  adhere, 
including probiotic Lactobacillus species. Numerous mechanisms for adhesion to mucus 
have  been  discovered  in  lactobacilli,  including  partially  characterized  mucus  binding 
proteins. These mechanisms vary in importance with the in vitro models studied, which 
could significantly affect the perceived probiotic potential of the organisms. Understanding 
the nature of mucus-microbe interactions could be the key to elucidating the mechanisms 
of probiotic adhesion within the host.  
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1. Introduction  
Lactobacilli  are  of  significant  importance  to  food  industries  due  to  their  involvement  in  the 
production  of  various  fermented  dairy,  meat,  and  vegetable  foods.  Also  important  to  the  health 
industry, lactobacilli are used as probiotics due to their health-promoting effects when consumed. One 
of the frequently exploited activities used to screen probiotic candidates is adhesion to the host gut, 
which is presumed to be requisite for sufficient host-interaction to confer health benefits [1]. Various 
in vitro models are used for the study of bacterial adhesion because of the complexity of studying the 
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in vivo system. However, these models are simplifications of in vivo situations, resulting in limited 
conclusions. One significant aspect of the gastrointestinal (GI) tract that is easy to overlook when 
studying bacterial adhesion, and choosing models with which to measure adhesion, is the presence of a 
mucus layer between the lumen and GI epithelial cells. The presence of mucus is particularly relevant 
in the colon, where mucus is thickest and microorganisms are most abundant. 
The  layer  of  mucus  bound  to  GI  epithelia  is  formed  from  a  continuous  gel  matrix  composed 
primarily of complex glycoproteins that acts as a barrier to protect the host from harmful antigens and 
promote luminal motility. This layer of mucus is the first physical barrier to host-cell stimulation by 
bacteria in the gut. Adhesion to this mucus is therefore the first step required for probiotic organisms to 
interact with host cells and elicit any particular response. In the human intestinal tract, the layer of 
mucus may vary in thickness from about 30 to 300 µm, generally increasing in thickness from the 
small intestine to the rectum, but the layer of mucus most closely bound to the epithelial layer rarely 
contains any bacteria at all [2,3].  
Numerous studies have characterized interactions between bacteria and host epithelia that induce 
alterations in host mucosal response [4–6] but how changes in mucus composition affect adhesion by 
gut microorganisms is not well understood. Likewise, exposure to mucus during growth has been 
shown  to  affect  bacterial  gene  expression  [7],  but  resulting  changes  to  adhesion  are  not  well 
recognized. Additionally, existing studies for bacterial adhesion show great variability due to a lack of 
standardization, complicating the interpretation of data from the current literature [8]. 
In this review, we will examine the composition of the mucus layers protecting GI epithelial tissue, 
which is considered to be the primary location of host-probiotic interaction [9]. Our focus will be on its 
relevance to Lactobacillus species, commensal bacteria of the human gut that are used extensively in 
commercial probiotic supplements and contain the most widely studied probiotic species in scientific 
literature. Our goal is to provide a framework for a better understanding of the role that mucus plays in 
probiotic-host interactions. 
2. Intestinal Mucus 
The epithelial tissue that forms the lining of the intestine is composed of various columnar cell 
types. Scattered across the length of the intestine, and all mucosal tissues, are goblet cells. These cells 
are unicellular glands that produce glycoproteins called mucins, which give mucus its characteristic 
viscoelastic  physical  properties.  Secreted  mucins  polymerize  to  form  the  matrix  that  provides  the 
structural  foundation  of  the  mucus  layer  resulting  in  protection  from  pathogens,  enzymes,  toxins, 
dehydration and abrasion [10]. Goblet cells produce secretory mucin at a basal constitutive level under 
normal physiological conditions to maintain this protective layer of mucus, which is exposed to the 
harsh luminal environment and constantly eroded by luminal particulates and intestinal peristalsis [11].  
Table  1  shows  a  reported  21  MUC  genes  code  for  the  protein  cores  of  mucins  in  humans. 
Gastrointestinal mucins are either translocated to the membrane surface or secreted into the mucous 
gel.  Mucins  are  also  either  neutral  or  acidic,  depending  on  their  glycosyl  modification.  These 
categories can be further subdivided to account for greater variation in mucin structure [12].  
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Table 1. Known human MUC genes, their functions and locations. 
Gene 
Organisms with known 
homologues 
1 
Function 
2 
GeneAtlas location of 
highest expression 
2 
Type 
Selected 
references 
MUC1  Dog, cow, mouse, rat, rabbit  Cellular signal transduction, barrier 
activity 
Lungs  Membrane  [13,14] 
MUC2  Chimpanzee, dog, chicken  Primary extracellular matrix constituent 
in colon, lubricant activity 
Colon  Secretory  [14,15] 
MUC3A  Rat, mouse  Involved in epithelial cell protection, 
adhesion modulation, and signaling 
Various  Membrane  [16] 
MUC3B  Rat, mouse  Unknown, possibly cellular signal 
transduction 
Various  Membrane  [16] 
MUC4  Many mammals, chicken, 
frog, platypus 
Involved in intestinal epithelial cell 
differentiation, renewal, lubrication 
Colon  Membrane  [17,18] 
MUC5B 
(MUC9) 
Chimpanzee, zebrafish, 
mouse, chicken, more 
Unknown, primarily lubricant  Various  Secretory  [19,20] 
MUC5AC  Chimpanzee, rat, zebrafish  Major component of airway mucus 
involved in intestinal epithelial cell 
differentiation 
Trachea, Lungs  Secretory  [21,22] 
MUC6  Chimpanzee, dog, mouse, 
chicken 
Unknown, involved in renal 
morphogenesis processes 
Pancreas, digestive and 
reproductive systems 
Secretory  [22–24] 
MUC7  Chimpanzee, cow, rat  Facilitating the clearance of oral 
bacteria 
Salivary Gland  Secretory  [25,26] 
MUC8  Unknown  Unknown  Trachea  Secretory  [27] 
MUC12 
(MUC11) 
Cow, M.grisea, N. crassa, 
rice 
May be involved in epithelial cell 
regulation 
Colon  Membrane  [28] 
MUC13  Chimpanzee, dog, mouse, rat  Barrier function in epithelial tissues  Pancreas, small intestine, 
colon 
Membrane  [29] 
EMCN 
(MUC14) 
Dog, cow, mouse, rat, 
chicken 
Interferes with the assembly of focal 
adhesion complexes 
Fetal lung, uterus, thyroid  Membrane  [30] 
MUC15  Chimpanzee, cow, mouse, rat  Barrier function in epithelial tissues  Testis leydig cell  Membrane  [31] 
MUC16 
(CA125) 
Chimpanzee, dog, mouse, 
chicken 
Unknown, plays a role in ovarian 
cancer 
Lymph nodes, respiratory 
tract 
Membrane  [32,33] 
MUC17 
(MUC3) 
Chimpanzee, S. pombe, 
S. cerevisiae, and K. lactis 
Extracellular matrix constituent, 
lubricant activity 
Small intestine, stomach  Membrane  [34,35] 
MCAM 
(MUC18, 
CD146) 
Chimpanzee, dog, mouse, rat, 
zebrafish 
AKA ―melanoma cell adhesion 
molecule‖, cell-cell adhesion 
Various  Membrane  [36,37] 
MUC19  Chimpanzee, dog, mouse, rat, 
frog 
Major gel-forming mucin in the human 
middle ear 
Secretory cells of the ears 
and eyes 
Secretory  [38] 
MUC20  Chimpanzee, dog, cow, 
mouse, rat 
Cellular signal transduction  Intestine, respiratory and 
urinary tract 
Membrane  [39] 
MUC21  Chimpanzee, cow, mosquito, 
and A. thaliana 
Unknown, mediates cell adhesion  Unknown  Membrane  [40,41] 
CD164 
(MUC24) 
Chimpanzee, dog, cow, 
mouse, rat, chicken, zebrafish 
Regulates stem cell localization to the 
bone marrow 
Thyroid, placenta, 
intestine, immune cells 
Membrane  [42] 
1 Via HomoloGene [43] database; 
2 via GenAtlas [44] and BioGPS [45] databases. Nutrients 2011, 3  
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Mucin Genes and Modifications  
Gastrointestinal  MUC  proteins  contain  characteristic  tandem  repeats  of  threonine,  proline,  and 
serine residues, where O-glycosidic linkages occur between the protein core and N-acetylgalactosamine 
(GalNAc) termini of oligosaccharides [46,47]. Neither the amino nor the carboxy termini of secretory 
mucins are generally glycosylated [48], but contain cysteine rich regions that promote intermolecular 
disulfide bonding (as shown in Figure 1). The dense glycosylation of the protein core and intermolecular 
bonding  of  the  terminal  regions  effectively  protects  the  mucin  polymers  from  protease  activity, 
preserving the protective structural matrix [49]. 
Figure 1. Diagram of the MUC2 protein core. The protein termini contain cysteine-rich 
regions homologous to von Willebrand Factor (vWF) domains (a); The N-terminal regions 
of MUC2 proteins contain vWF domain homologs D1, D2, D′, and D3 and the C-terminal 
regions contain vWF domain homologs D4, B, C, and CK. These terminal domains are 
responsible  for  the  extensive  polymerization  between  mucin  monomers,  along  with 
the cysteine  rich  interruptions  between  glycosylated  tandem  repeats  (b);  The  first  of 
two repetitive domains (c) contains 21 repeats of an irregular motif, whereas the second 
domain (d) is formed of 50–115 tandem 23aa motifs (PTTTPITTTTTVTPTPTPTGTQT). 
Threonines in the repeats are O-glycosylated, forming a densely packed envelope of short, 
branched carbohydrate chains surrounding these regions. 
 
The  predominant  genes  expressing  membrane-bound  mucins  in  human  colonic  goblet  cells  are 
MUC1,  MUC3A/B,  MUC4,  and  MUC12.  Membrane-bound  mucins  could  play  a  role  in 
immunomodulatory effects of bacterial interactions with the epithelial membrane when the secretory 
mucin  matrix  is  bypassed  [50],  however  bacteria  more  frequently  come  in  contact  with  secretory 
mucins considering the majority of bacteria only inhabit the outer portions of the mucus layers [51]. 
MUC2 is the principal secretory mucin gene expressed in the colon, comprising the majority of the 
mucous  gel  protecting  the  underlying  tissue  [52].  The  role  and  mechanisms  of  mucin  in  innate 
immunity is reviewed more thoroughly by Dharmani et al. [53] and for a more detailed structural 
analysis of MUC2, see Allen et al. [15]. 
Oligosaccharide chains are affixed to MUC proteins by membrane-bound transferases in the Golgi 
apparatus and endoplasmic reticulum of goblet cells. GalNAc is affixed to the mucin protein from a 
sugar-nucleotide donor and a collection of specific glycosyltransferases continues to add residues, 
resulting  in  an  oligosaccharide  with  a  particular  structure  and  terminus  [54,55].  Glycosylation 
biosynthesis pathways are highly complex; glycosyltransferase gene expression levels, variability in 
spatiotemporal concentrations of enzymes, cofactors, and substrates, as well as the number of branching 
configurations possible all contribute to the wide range of potential protein-modifications [55]. This 
leads to glycoproteins forming from the same mucin gene product that will vary in glycan modification 
with location or tissue. Nutrients 2011, 3  
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The oligosaccharide modifications can comprise up to 80% of the weight of a mucin and vary in 
length and structure. Secreted colonic mucins commonly contain side-chains of 4–15 monosaccharides 
with galactose and GalNAc backbones and branched chains terminating with GalNAc, fucose, or sialic 
(neuraminic) acid to varying degrees [56,57]. 
The  predominance  of  acidic  mucin  subtypes,  those  with  side-chains  containing  terminal  ester 
sulfates and sialic acid groups, varies by location in the GI tract from species to species, as does the 
type of acidic modification most heavily expressed [58]. The presence of acidic side-chains can result 
in greater inhibition of bacterial growth in vitro [59] and reduced enzymatic degradation [60,61], but 
what causes the prevalence of these modifications in different parts of GI tissues is likely due to the 
tissue-dependence of specific collections of glycosyltransferase enzymes [62]. 
Intestinal mucin polymers are considered nutritive glycans for commensal bacteria in the promotion 
of their residence and associated benefits [63,64]. Host glycosylation patterns in the gut may have 
coevolved with intestinal microbiota to accommodate the filling of niches beneficial to the host [65,66]. 
Host provision of mucin oligosaccharides specific to particular bacterial enzymes could provide a 
nutritional  advantage  to  bacteria  with  those  enzymes  and  differential  expression  of  mucin 
oligosaccharides  by  tissue  could  hypothetically  regulate  host-microbe  interactions  to  direct certain 
microbial populations to fill particular host-niches. So-called host ―legislation‖ of glycosylation to 
promote  particular  microbial  populations  is  evaluated  in  greater  depth  in  a  review  by  Patsos  and 
Corfield [67]. Whether this plays a crucial role in Lactobacillus adhesion or is primarily a mechanism 
of promoting maintenance of other commensal microbiota is currently unclear. 
One  broad  example  of  host  legislation  comes  from  the  analysis  of  mucin  oligosaccharide 
composition along the human intestinal tract, which showed that certain glycosylation patterns were 
conserved regionally despite inter-individual variation [68]. A gradient of sialylated mucin concentration 
was observed, decreasing from the ileum to the colon, running against an increasing gradient of more 
heavily fucosylated mucin. 
A more specific example of microbial legislation by hosts lies in the presence of O-glycans on 
mucin that exhibit Lewis type or blood group ABO antigens. The secretor genes that determine host 
blood type also control the specificity of the ABO blood group type terminal glycosides of certain 
mucin  oligosaccharide  chains  [69].  The  glycosyltransferase  responsible  for  blood  group  antigen 
precursors has been identified in secretory tissues producing mucins and glycoproteins [70]. There is 
evidence that populations of bacteria that produce specific blood type antigen-degrading glycosidases 
are present at levels 50,000 times greater in individuals with that particular blood type [71].  
While evidence of mucin oligosaccharide degradation by bacteria is fairly well established [64,72–75], 
the dramatic impact of blood type on the composition of enteric microbial populations could imply that 
there  is  some  degree  of  binding  preference  at  play  with  host  glycan  legislation  as  well.  This  is 
supported  by  evidence  of  bacteria  binding  with  human  milk  oligosaccharides,  which  can  exhibit 
structural similarities with mucin oligosaccharides and blood type antigens [76].  
Glycosidases of lactic acid bacteria have been fairly well characterized in terms of oligosaccharide 
breakdown  and  metabolism  [77,78],  but  knowledge  of  glycoconjugate  adhesion  remains  poorly 
described.  Figure  2  displays  a  model  of  molecular  binding  mechanisms  that  may  play  a  role  in  
host-bacteria interactions. Elucidation of these binding mechanisms may be the key to understanding 
adhesion of lactobacilli in the gut. Nutrients 2011, 3  
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Figure 2. Simplified histological cross-section of microbial adhesion to the colonic mucosal surface at various magnifications. (a) The layer 
of mucus atop colonic epithelial villi. Goblet cells can be seen interspersed throughout the columnar enterocytes, producing secretory mucin 
that  makes up  the  gel  matrix.  The  microbial communities  residing in  and  on  top  of  the  mucus  layer  can  only  be  found  at  substantial 
concentrations in the outermost regions of the mucus; (b) The mucus-bacteria interface. The mucin molecules polymerize to form the mucus 
layer  matrix  to  which  cells  adhere.  Extensive  disulfide  bonding  between  cysteine-rich  regions  of  the  mucin  protein  cores  creates  the 
characteristic viscoelastic properties of mucus. Oligosaccharide modifications of mucin protein cores form ―bottle-brush‖ regions providing 
substrate for adhesion to binding proteins on bacterial cell surfaces; (c) A proposed molecular mechanism of adhesion. Evidence suggests that 
putative mucin-binding proteins anchored to the bacterial cell wall may interact with the glycosyl modifications of the mucin proteins to 
promote adhesion of the cell to the mucus layer. Mucin oligosaccharide structures vary due to tissue and cell-specific glycosyltransferase 
expression levels, so the specificity of particular oligosaccharide moieties may lead to preferential binding of particular bacteria to different 
host niches. 
 Nutrients 2011, 3  
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For  a  more  detailed  characterization  of  mucin  production,  structure,  and  host  function  see  the 
review by Lindé n et al. [79]. Further information on the study of mucin glycomics, including identified 
O-linked  glycan modifications characteristic of  GI mucin  and  their biosynthetic  pathways,  can be 
obtained from glycobiology resources such as the Kyoto Encyclopedia of Genes and Genomes [80] 
and the Consortium for Functional Glycomics [81]. 
3. Adhesion 
Most clinical studies of probiotic persistence and colonization show that probiotic organisms do not 
permanently colonize the GI tract and continue providing their hosts benefits only for brief periods 
after they have stopped being administered [82,83]. Little is known of what makes probiotic organisms 
so  transient  relative  to  commensals,  so  it  is  important  to  consider  the  factors  influencing  their 
capability  to  adhere  and  persist  in  the  gut  when  studying  and  manipulating  probiotic  organisms. 
Bacteria  adhere  initially  to  GI  surfaces  by  nonspecific  physical  interactions,  such  as  steric  and 
hydrophobic interactions, which result in reversible attachment. Several researchers have reported that 
there is a degree of correlation between hydrophobicity and adhesion to the hydrophobic mucosal 
surface [84–87]. However, other studies indicated that there was no correlation between cell surface 
hydrophobicity and adhesion to intestinal mucus [88,89]. In these studies, highly adhesive bacteria 
demonstrated fairly low surface hydrophobicities. This has suggested that cell surface hydrophobicity 
is not an accurate measure of adhesive potential.  
While adhesive characteristics of lactobacilli vary considerably among strains and species [90–92], 
many have large surface proteins with highly repetitive structures that are involved in mucus adhesion. 
Though specific mechanisms are not yet well understood, evidence suggests that carbohydrate-protein 
interactions play a key role in the adhesion of these proteins to mucin-bound oligosaccharides, especially 
considering numerous mucus-binding proteins contain regions homologous with binding domains of 
other known proteins such as lectins. The evolution of lectin-like adhesins in endosymbiotic bacteria 
may have been favored by the presence of multivalent substrates such as the mucins found in the GI 
tract. Affinities of lectins for multivalent glycoproteins can be 50-fold to 10
6-fold greater than for 
individual glycan moieties [93]. Recently, a number of mucus-binding proteins have been isolated, 
some  of  which  have  been  shown  to  display  lectin-like  interactions,  and  some  of  which  may  be 
conserved in numerous Lactobacillus species. 
3.1. Mucus Binding Proteins 
Several lactobacilli proteins have been shown to promote mucus adhesion (Table 2). The most 
studied example of mucus-targeting bacterial adhesins is the mucus-binding protein, MUB, produced 
by  L.  reuteri  [82,94].  The  MUB  protein  contains  repeated  functional  domains,  referred  to  by  the 
authors as Mub domains, which are responsible for the protein’s adhesive properties. The Mub domain 
has since been designated a member of the MucBP domain family (Pfam PF06458). Numerous MUB 
homologues and MucBP domain containing proteins have been found, but almost exclusively in lactic 
acid bacteria and predominantly in lactobacilli found naturally in intestinal niches (Table 3). This 
suggests that MucBP domain containing proteins play an important role in establishing host-microbial 
interactions in the gut and promoted the evolution of the species as primarily GI organisms [93,95–97].  Nutrients 2011, 3  
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Table 2. Adhesion promoting proteins in Lactobacillus spp. 
Protein  Info.  Species  References 
MUB  Demonstrates binding to mucus in vitro  L. reuteri  [95] 
MucBP Domain 
Containing Proteins 
Contain MucBP domains, implicated in mucus adhesion  13 known Lactobacillus spp.  [98] 
Pili  Pilin subunit SpaC binds to mucus in vitro  L. johnsonii, L. rhamnosus  [99–101] 
32-Mmubp  Demonstrates binding to mucus in vitro  L. fermentum  [102] 
SlpA  Knockouts show diminished adhesion to mucus in vitro  L. acidophilus  [103] 
Msa  Demonstrates binding of mannose in vitro  L. plantarum  [104] 
MapA  Demonstrates binding to mucus in vitro  L. reuteri  [105,106] 
EF-Tu  Expression upregulated in the presence of mucus  L. johnsonii  [107–111] 
Table 3. MucBP domain containing sequences in available Lactobacillus genomes. 
Currently available whole genomes  Accession#  Gene  # of domains  Size 
Lactobacillus acidophilus NCFM   Q5FKK8  LBA0909  1  508aa 
   Q5FKA8  LBA1017  1  294aa 
   Q5FKA7  LBA1018  1  346aa 
   Q5FKA6  LBA1019  7  2650aa 
   Q5FKA5  LBA1020  5  2310aa 
   Q5FJS1  LBA1218  1  697aa 
   Q5FJC2  LBA1377  2  1017aa 
   Q5FJA7  LBA1392  17  4326aa 
   Q5FJ43  LBA1460  2  339aa 
   Q5FIQ0  LBA1609  2  643aa 
   Q5FIL0  LBA1652  3  1174aa 
   Q5FIF3  LBA1709  3  1208aa 
Lactobacillus brevis ATCC 367   Q03U29  LVIS_0122  2  912aa 
   Q03T21  LVIS_0493  3  1519aa 
   Q03P66  LVIS_1947  1  1111aa 
   Q03NB2  LVIS_2262  1  422aa 
Lactobacillus crispatus ST1   D5H0E1  LCRIS_00029  3  1232aa 
   D5H2Y1  LCRIS_00919  7  2935aa 
   D5GXR1  LCRIS_01123  1  304aa 
   D5GZ92  LCRIS_01654  2  3552aa 
Lactobacillus fermentum IFO 3956   B2GFA4  LAF_0157  1  208aa 
   B2GBH7  LAF_0673  2  1059aa 
Lactobacillus gasseri ATCC 33323   Q047B3  LGAS_0044  4  873aa 
   Q047B2  LGAS_0045  11  3692aa 
   Q047B1  LGAS_0046  4  985aa 
   Q046R7  LGAS_0143  6  2823aa 
   Q045Q7  LGAS_0410  5  2457aa 
   Q043P5  LGAS_0939  2  615aa 
   Q043P2  LGAS_0942  10  2833aa 
   Q043P0  LGAS_0944  1  524aa 
   Q041C4  LGAS_1655  2  1425aa 
   Q041B7  LGAS_1663  6  2449aa Nutrients 2011, 3  
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Table 3. Cont. 
   Q041A9  LGAS_1671  4  2552aa 
   Q040V9  LGAS_1725  6  1993aa 
Lactobacillus helveticus DPC 4571   A8YTV1  lhv_0494  1  155aa 
   A8YTV2  lhv_0495  1  178aa 
   A8YUX0  lhv_0973  1  278aa 
   A8YUX3  lhv_0979  1  858aa 
Lactobacillus johnsonii FI9785   D0R4C3  FI9785_1070  6  3401aa 
   D0R5H6  FI9785_1482  5  1356aa 
Lactobacillus johnsonii NCC 533  Q74LY7  LJ_0046  4  870aa 
   Q74LY6  LJ_0047  6  2139aa 
   Q74LY5  LJ_0048  4  983aa 
   Q74L43  LJ_0382  4  3619aa 
   Q74KU3  LJ_0484  4  4037aa 
   Q74HP3  LJ_0574  5  1571aa 
   Q74HU0  LJ_0621  5  2789aa 
   Q74HW0  LJ_0641  3  1563aa 
   Q74HA8  LJ_1839  7  1814aa 
Lactobacillus plantarum JDM1   C6VP10  JDM1_1038  4  1082aa 
   C6VQ03  JDM1_1381  6  2219aa 
   C6VKM3  JDM1_2438  4  1345aa 
   C6VL52  JDM1_2491  4  2037aa 
   C6VL55  JDM1_2494  1  750aa 
Lactobacillus plantarum WCFS1   Q88Y49  lp_0946  1  1189aa 
   Q88XH5  lp_1229  3  1010aa 
   Q88WI9  lp_1643  6  2219aa 
   Q88UJ0  lp_2486  2  917aa 
   Q88TB8  lp_3059  4  1356aa 
   Q88T70  lp_3114  4  2032aa 
   Q88T67  lp_3117  1  750aa 
Lactobacillus reuteri DSM 20016   A5VKZ1  Lreu_1258  1  745aa 
Lactobacillus reuteri JCM 1112   B2G8C6  LAR_1192  1  745aa 
Lactobacillus salivarius CECT 5713   D8IM74  HN6_01114  4  785aa 
Lactobacillus salivarius UCC118   Q1WSI9  LSL_1335  4  785aa 
Data gathered from the Pfam [112] and Uniprot [113] databases; Databases contained no MucBP domain 
containing sequences in Lactobacillus delbrueckii subsp. bulgaricus strains ATCC 11842 and ATCC BAA-365, 
Lactobacillus  fermentum  CECT  5716,  Lactobacillus  casei  strains  Zhang,  BL23,  and  ATCC334, 
Lactobacillus plantarum subsp. plantarum ST-III,  Lactobacillus rhamnosus strains GG and Lc 705, and 
Lactobacillus sakei subsp. sakei 23K. 
MUB and most MucBP domain containing proteins exhibit characteristics typical of Gram-positive 
cell surface proteins; a C-terminal sortase recognition motif (LPXTG) for anchoring the protein to 
peptidoglycan,  repeated  functional  domains  and  an  N-terminal  region  signaling  the  protein  for 
secretion [94,95]. 
Roos and Jonsson’s competitive adhesion study showed that the binding of MUB to mucus was 
inhibited by the glycoproteins fetuin and asialofetuin as well as fucose, suggesting that MUB interacts Nutrients 2011, 3  
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with specific muco-oligosaccharides [94]. The study also demonstrated equivalent adhesion to mucus 
from different hosts indicating that MUB binding has little to no host specificity regarding mucus 
components.  The  recent  resolution  of  the  crystal  structure  of  a  MucBP  domain  in  MUB,  dubbed  
Mub2  [92],  and  subsequent  discovery  of  immunoglobulin  binding,  provides  further  evidence  of  a 
broad  binding  specificity.  This  suggests  that  binding  specificities  of  MucBP  domain  containing 
proteins are dictated by multiple factors, not solely resulting from the presence of MucBP domains. 
Fimbrial genes have been reported in L. johnsonii NCC533 [99], but the direct visualization of pili 
on Lactobacillus cells has only been shown for L. rhamnosus GG [100]. Fimbriae, also referred to as 
pili, are thin proteinaceous extensions from bacterial cells, predominantly in Gram-negative bacteria, 
that promote adhesion. In many pathogens, pili are virulence factors that promote attachment to the 
host [101]. Kankainen et al. [100] isolated a pilin subunit, SpaC, located within the pili structure and 
found at the pilus tip, which was concluded to be essential to the interaction of L. rhamnosus GG with 
host mucus. A mutant strain lacking spaC expression showed significantly reduced binding. While 
these genes are uncommon among lactobacilli, this study has shown for the first time that fimbrial 
interaction with mucus can mediate host adhesion in lactobacilli.  
SlpA, an S-layer protein in L. acidophilus, has been implicated in promoting adhesion directly to 
the GI surface, because slpA knockouts showed decreased adhesion capability [103]. However, this 
could possibly be due to disruption of other surface proteins. S-layer proteins and glycoproteins can 
form a latticed monolayer coating the surface of bacterial cells [114]. S-layer components can vary 
widely by species, but function to protect the cell from enzymatic damage, low pH, bacteriophages and 
phagocytosis. While S-layers are present in only some Lactobacillus species, they are beginning to be 
studied for their adhesive functions. A number of studies have begun associating S-layer proteins in 
probiotic bacteria with competitive exclusion of pathogens and pathogen adhesion to mucus [115–117]. 
Certain other surface proteins are implicated in contributing to adhesive properties of lactobacilli 
but are otherwise not well characterized or their importance to adhesive mechanisms is poorly defined. 
For instance, a 32 kDa protein associated with adhesion to porcine mucus in L. fermentum, named  
32-Mmubp,  was  identified  as  a  homologue  of  the  substrate  binding  domains  of  the  OpuAC  
ABC-transport  protein  family  [102].  A  mannose-specific  adhesin  protein  (Msa,  a  MucBP  domain 
containing protein) is responsible for the binding of mannose by L. plantarum [104]. While this was 
initially discovered as a protein responsible for agglutinating Saccharomyces cerevisiae, the presence 
of L. plantarum in many intestinal niches suggests that the MucBP domains of Msa may also play a 
role  in  adhesion  to  non-mannosylated  muco-oligosaccharides  as  well.  Elongation  Factor  Tu  is  a 
guanosine  binding  protein  that  is  important  in  protein  synthesis  in  the  cytoplasm,  but  has  been 
identified as a membrane associated protein as well [107,108]. More recently it has been found on the 
cell surfaces of many lactobacilli [109,110] and the demonstration of its upregulation in the presence 
of mucus suggests it may play a role in adhesion to the GI tract [111]. Mucus adhesion-promoting 
protein (MapA) is reported to mediate the binding of L. reuteri and L. fermentum to mucus [105,106]. 
Interestingly, it is also degraded into an antimicrobial peptide, which lends the host anti-pathogenic 
properties and provides an example of how large surface proteins may exhibit evolutionarily beneficial 
pleiotropic effects [118]. 
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3.2. Factors that Influence Binding in Vivo and in Vitro 
Numerous factors have been shown to influence binding of lactobacilli to mucus in vitro. Certain 
aspects of experimental design in particular should be reviewed when choosing or comparing methods 
to  study  adhesion  in  vitro  because  of  the  direct  effects  they  have  on  adhesion.  Time  allotted  for 
incubation of bacteria on immobilized mucus can have a significant influence on observed adhesion if 
microbial sedimentation occurs and the substrate is saturated at an artificial level [119].  
Ramiah et al. [111] showed that growth conditions mimicking the GI environment have significant 
effects on the expression of several mucus adhesins in vitro in L. plantarum. MapA was upregulated  
6–8-fold when incubated in the presence of mucin and up to 25-fold when exposed to physiological 
concentrations of pancreatin and bile compared to MRS grown controls. It was also found that mapA 
was significantly downregulated in the presence of cysteine, and suggested that cysteine is an effector 
molecule that represses transcription of mapA. Mub was expressed 80–140-fold more in the presence 
of mucin, but was suppressed 7–30-fold under normal gut physiological conditions containing bile and 
pancreatin.  EF-Tu  was  expressed  33–100  times  greater  in  media  containing  mucus,  but  was  not 
affected  by  bile  or  pancreatin  concentrations.  This  may  connote  interplay  between  different 
mechanisms regulating adhesin expression to adapt to particular environments. 
The possible mechanisms whereby food components affect the adhesion of probiotic organisms 
in vivo have not been investigated thoroughly. Exposure to milk and milk fatty acids has been observed 
to reduce the adhesive properties of some probiotic lactobacilli [120,121] to human intestinal mucus 
in vitro, which may also be relevant in vivo. It is also hypothesized that entrapment in food matrices 
in vivo, resulting in binding to or steric hindrance of adhesins, can decrease adhesion of bacteria to 
intestinal surfaces [119]. 
All bacterial adhesion in the gut is also likely inhibited to some degree by competitive exclusion of 
access to binding sites by commensal organisms, but quantification of these effects have yet to be 
studied thoroughly. 
4. In Vitro Models 
Adhesion  to  the  GI  tract  has  been  widely  used  as  a  criterion  for  the  selection  of  probiotic 
lactobacilli [122]. It has generally been assumed that probiotic efficacy is enhanced by adhesion to the 
GI  tract,  which  increases  residence  time  in  vivo.  This  extends  the  period  during  which  probiotic 
organisms can exert beneficial effects, such as immune stimulation from contact with the intestinal 
tract [123,124]. However, it is difficult to link adhesion, specifically, with probiotic efficacy. Studies 
with isogenic strains containing adhesion factor knockouts [125] demonstrate decreased adhesion to 
the gut, however it is not known how such a knockout would alter probiotic efficacy. Adhesion has 
been  demonstrated  as  an  important  factor  in  the  displacement  of  pathogens  by  probiotic  bacteria 
in vitro  [126–128],  but  isolating  the  influence  of  adhesion  in  vivo  is  complicated  by  various 
confounded factors. The effects of probiotic bacteria stem not only from adhesion to the GI tract and 
competition  for  binding  sites  with  pathogens,  but  from  competition  for  nutrients  as  well  as  the 
production of exogenous antimicrobial and immune-stimulating compounds. Some studies do correlate 
adhesive capacity with immune response [129,130], but it is uncertain to what extent confounded Nutrients 2011, 3  
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factors may influence observed probiotic activity. Understanding the molecular mechanisms behind 
microbial adhesion in the gut could help determine the degree of probiotic functionality imparted by 
adhesion alone. 
The  validity  of  the  experimental  models  used  in  the  measurement  of  probiotic  adhesion  may, 
however, be difficult to interpret. No standard model for in vitro adhesion exists so findings vary 
widely not only between strains and species, but between models as well [131]. The in vitro model 
determines the nature of adhesion sites in the system; some cell culture models will emphasize the 
measurement of direct host-microbe cellular contact, whereas mucus-secreting cultures or immobilized 
mucus models will emphasize mucus and muco-oligosaccharide interactions more than other models. 
As  summarized  in  Table  4,  there  are  advantages  and  disadvantages  to  various  types  of  in  vitro 
adhesion models. It may therefore be important to study adhesion in vitro via different methods for a 
more thorough understanding of the interaction mechanisms most important to probiotic adhesion. 
Table 4. Summary of in vitro adhesion models. 
Model  Description  Advantages  Disadvantages  References 
Immobilized 
mucus 
Mucus preparations 
immobilized, usually in 
microtitre wells 
Fast, isolates mucus-
microbe interactions from 
other in vivo conditions 
Difficult to separate mucus-
specific from hydrophobic 
interactions 
[91,131–133] 
Cell culture  Polar monolayer of 
enterocytes resembling 
intestinal tissue 
Provides conditions more 
similar to in vivo 
environment 
Derived from cancer cells, could 
differ from healthy tissue. Not 
representative of cell-type ratios 
in mucosal epithelial tissues 
 
Caco-2/HT29 Caco-2 and HT29 carcinoma 
cell lines 
Simple, well established 
in literature 
Does not account for mucus 
presence 
[134–137] 
HT29-MTX/FU HT29 culture treated with 
methotrexate or fluoruracil to 
secret mucus of different types 
Accounts for presence of 
mucus 
May not represent appropriate 
MUC gene expression 
[138–144] 
Co-cultures Mixed culture of secreting and 
mucus-secreting cells 
Better represents cell-
type ratio of mucosal 
epithelial tissues 
Little literature for use in 
adhesion studies 
[145–147] 
Whole tissue  Whole, intact or excised tissue  Provides in vitro 
conditions most similar to 
in vivo environment 
Costly, difficult to obtain   
Resected tissue Fragments of tissue excised 
from host 
Mucus, epithelial tissue, 
and commensal 
organisms accounted for 
in model 
Only small fragments at a time 
available from living hosts 
[148,149] 
Organ culture Whole organs maintained 
in vitro 
Better maintains the 
architecture of the tissue 
Prohibitively expensive, may 
not function in same manner as 
in vivo 
[150,151] 
4.1. Mucus Adhesion Models 
The simplest method to measure the adhesion of bacterial strains to mucus is by immobilizing 
commercially available mucin. Mucin is bound to microtitre well plates, bacterial culture is bound  Nutrients 2011, 3  
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to  the  mucin  and  strains  are  compared  thereafter  in  any  number  of  methods,  qualitatively  or 
quantitatively [91,132,133]. The use of mucin alone in adhesion assays allows for the targeting of 
interactions between bacteria and particular mucins known to be expressed in a given host locations.  
It  also  isolates  microbe-mucus  interactions  from  other  interactions,  such  as  host  cell-microbe 
interactions, which may or may not be desirable. One drawback of this model is the complication of 
microbial  hydrophobic  properties  with  mucus-binding  properties.  The  comparison  of  hydrophobic 
binding interactions of bacteria to untreated polycarbonate wells with mucus binding interactions in 
treated wells in one study [131] showed that hydrophobic binding interactions are not easily separable 
from mucus binding interactions. 
4.2. Cell-Culture Models 
Cultures  of  human  intestinal  cell  lines  are  often  presumed  to  better  represent  the  environment 
in vivo because of the presence of actual tissue. The availability of a simple in vitro intestinal tissue 
model, as in the Caco-2 cell line, has provided valuable insight into cellular interaction mechanisms 
that would have been much more difficult to obtain with more complex in vitro techniques or in vivo. 
Caco-2 and HT29 cells, the two most commonly used intestinal cell lines, can be grown in culture to 
form  a  homogeneous  polar  monolayer  of  mature  enterocytes  resembling  the  tissue  of  the  small 
intestine [134]. These models were developed primarily for the study of absorption and permeability in 
the small intestine and are derived from intestinal carcinomas, so they may or may not be accurate 
models  for adhesion to healthy  colonic tissue [135].  Several studies have compared the extent of  
Caco-2 cell binding by potential probiotic bacteria to adhesion in vivo with mixed results [136,137]. 
Regardless, these cell lines do not take into account the omnipresent mucus layer found in the healthy 
intestinal tract. The HT29 cell line, however, can be treated with methotrexate (MTX) to differentiate 
the cells into mucin-secreting goblet cells [138,139]. The production of mucus by HT29-MTX cells 
increase  adhesion  of  bacterial  cells  relative  to  Caco-2  or  HT29  cells  alone  [140,141],  further 
supporting the importance of the presence of mucus to bacterial adhesion.  
The HT29-MTX line is composed primarily of goblet cells, which incorporates a mucus layer into 
the model, but it still does not accurately represent the enterocyte/goblet cell ratio of the gut epithelial 
layer. In response to this drawback, Caco-2/HT29-MTX co-cultures have been developed [145–147]. 
Unfortunately,  HT29-MTX  differentiated  goblet  cells  express  MUC5AC  and  MUC5B  at  a  much 
greater  rate  than  MUC2  [139],  which  could  be  a  significant  drawback  when  studying  microbial 
adhesion to the colon, where MUC2 is prevalent. HT29 cells also differentiate in the presence of  
5-fluorouracil (FU) to secrete MUC2 [142], and while this would emulate the colonic environment 
more  closely,  the HT29-FU  model only seems  to  have been used in  the study of pathogens  thus  
far [139,140].  
4.3. Whole Tissue Models 
The disadvantage of many models is that they don’t take into account the presence of normal GI 
microbiota and the competitive exclusion that would take place in vivo between established commensal 
populations  and  exogenous  microbes.  For  a  more  complete  model  of  intestinal  tissue  in  vitro, 
encompassing the mucus layer and epithelial tissue accurately, but also accounting for the presence of Nutrients 2011, 3  
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commensal microbiota, whole intestinal tissue fragments can be used [148,149]. Resected fragments of 
healthy  colonic tissue  may  be  difficult  to  obtain,  but likely  display characteristics  closer  to  those 
probiotic bacteria would be expected to encounter in vivo than other models. Similarly, organ culture 
can be employed to maintain the viability and architecture of the tissue and has been used to assess 
adhesive properties of pathogens [150,151]. As of yet, it does not seem that organ culture has been 
used in the study of probiotic organisms; the expense of using organ culture is more easily justifiable 
with  pathogenic  organisms  that  could  not  otherwise  be  used  in  human  models  safely,  unlike  
probiotic organisms. 
5. Conclusion 
As the field advances, discovery and selection of better probiotic organisms will become more 
sophisticated.  Refinement  of  cell-culture  techniques  to  better  represent  colonic  environment  could 
provide  more  accurate  measures  of  adhesion,  further  aiding  the  selection  of  the  best  probiotic 
candidates for clinical trials. Printed glycan microarrays are beginning to be used to elaborate binding 
patterns  of  whole  bacterial  cells  to  different  glycan  structures  [152].  Discoveries  using  similar 
techniques  could  promote  the  understanding  of  specific  affinities  for  different  binding  proteins. 
Determining the structural characteristics and binding specificities of mucus-binding proteins improve 
our understanding of the mechanisms behind probiotic-host interactions. This could in turn lead to the 
development of better tools to select the most beneficial probiotic organisms, potentially opening the 
door  for  designer  probiotics  engineered  or  selected  for  desired  host-responses.  Likewise,  a  better 
understanding of host glycosyl legislation in the context of bacterial binding specificity could result in 
the development of probiotics targeted for specific hosts or host tissue.  
Regardless of what future advances may come, knowledge of the limitations within the study of 
bacterial adhesion, as in any field, should help in the interpretation of current discovery as well as with 
the planning of further research. 
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